Table 4

Relationship of regimens of HRT to prognostic factors among women with lobular breast cancer

VariableNever used HRT (N = 113)Used ERTa (N = 92b)Used S-CHRTc (N = 63b)Used C-CHRTd (N = 79b)
N (%)N (%)OR95% CIN (%)OR95% CIN (%)OR95% CI
Tumor sizec
 <2 cm53 (52.0)46 (51.1)1.0Ref.f37 (59.7)1.0Ref.42 (54.5)1.0Ref.
 2 to <5 cm36 (35.3)31 (34.4)1.00.5–2.019 (30.6)1.00.4–2.125 (32.5)1.00.5–2.0
 5+ cm13 (12.7)13 (14.4)1.10.4–2.96 (9.7)0.50.2–1.610 (13.0)0.80.3–2.1
Tumor sizeg
 <2 cm53 (52.0)46 (51.1)1.0Ref.37 (59.7)1.0Ref.42 (54.5)1.0Ref.
 2 to <5 cm36 (35.3)31 (34.4)1.50.7–3.019 (30.6)1.60.7–3.825 (32.5)1.30.6–2.7
 5+ cm13 (12.7)13 (14.4)2.30.8–6.66 (9.7)1.50.4–5.810 (13.0)1.50.5–4.8
Stagee
 Local66 (58.9)62 (67.4)1.0Ref.44 (69.8)1.0Ref.45 (57.7)1.0Ref.
 Regional/distant46 (41.1)30 (32.6)0.70.4–1.319 (30.2)0.70.3–1.533 (42.3)1.10.6–2.2
Stageg
 Local66 (58.9)62 (67.4)1.0Ref.44 (69.8)1.0Ref.45 (57.7)1.0Ref.
 Regional/distant46 (41.1)30 (32.6)0.90.5–1.819 (30.2)1.10.5–2.633 (42.3)1.60.8–3.2
ER/PR statuse
 ER+83 (88.3)72 (85.7)1.0Ref.48 (88.9)1.0Ref.65 (92.9)1.0Ref.
 ER−11 (11.7)12 (14.3)1.50.5–4.26 (11.1)0.60.2–1.95 (7.1)0.50.1–1.6
 PR+69 (78.4)65 (81.3)1.0Ref.40 (78.4)1.0Ref.57 (90.5)1.0Ref.
 PR−19 (21.6)15 (18.8)0.70.3–1.611 (21.6)0.50.2–1.56 (9.5)0.20.1–0.6
  • a ERT, unopposed estrogen.

  • b Women could have used more than one regimen.

  • c S-CHRT, sequential estrogen plus progestin use (5–24 days/month).

  • d C-CHRT, continuous combined estrogen plus progestin use (25+ days/month).

  • e Used ≥6 months relative to never users of HRT; adjusted for age, race, and study site.

  • f Ref., referent.

  • g Used ≥6 months relative to never users of HRT; adjusted for age, race, study site, and screening mammogram in 2 years before reference.